In addition to functioning as an LGMN receptor on GBM cells, integrin αv has been shown to be an osteopontin receptor on macrophages and a TFPI2 receptor on microglia to mediate their polarization toward an immunosuppressive phenotype (24, 25); cilengitide may also inhibit macrophage and microglia immunosuppressive polarization in the GBM TME, thus further activating CD8+ T cell–mediated antitumor immunity and enhancing antitumor efficiency of immunotherapies. Here, CD8A is linked to glioblastoma.